Welcome to our dedicated page for Intorio SEC filings (Ticker: ITOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Intorio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Intorio's regulatory disclosures and financial reporting.
REDOX International Group, Corp. (ITOR) filed a Form 12b-25 (NT 10-Q), stating it cannot file its Quarterly Report on Form 10-Q for the period ended August 31, 2025 without unreasonable effort and expense.
The company is completing its financial statement review and believes the Form 10-Q will be filed within the period described under Rule 12b-25(b)(2)(ii).
Redox International Group filed an amendment to correct details about prior resales of restricted common stock by company affiliates. The original disclosure said 1,725,000 restricted shares were resold to eleven non-U.S. purchasers; the corrected figure is 1,325,000 shares sold to eight non-U.S. purchasers outside the United States.
Between August 6, 2024 and January 15, 2025, affiliates Dr. Han-Wen Ou and Mr. Hsun-Chih Lee resold these restricted shares in private transactions before the one-year distribution compliance period under Regulation S Rule 904 had expired. The board acknowledged that these resales may have been technical violations of Section 5 because of the early affiliate sales. Both individuals made written rescission offers at the original purchase price, none of which were accepted, and the company believes this reduces the risk of contingent liability and future enforcement or private claims.
Redox International Group filed an amendment to correct details about prior resales of restricted common stock by company affiliates. The original disclosure said 1,725,000 restricted shares were resold to eleven non-U.S. purchasers; the corrected figure is 1,325,000 shares sold to eight non-U.S. purchasers outside the United States.
Between August 6, 2024 and January 15, 2025, affiliates Dr. Han-Wen Ou and Mr. Hsun-Chih Lee resold these restricted shares in private transactions before the one-year distribution compliance period under Regulation S Rule 904 had expired. The board acknowledged that these resales may have been technical violations of Section 5 because of the early affiliate sales. Both individuals made written rescission offers at the original purchase price, none of which were accepted, and the company believes this reduces the risk of contingent liability and future enforcement or private claims.
Redox International Group filed an amendment to correct details about prior resales of restricted common stock by company affiliates. The original disclosure said 1,725,000 restricted shares were resold to eleven non-U.S. purchasers; the corrected figure is 1,325,000 shares sold to eight non-U.S. purchasers outside the United States.
Between August 6, 2024 and January 15, 2025, affiliates Dr. Han-Wen Ou and Mr. Hsun-Chih Lee resold these restricted shares in private transactions before the one-year distribution compliance period under Regulation S Rule 904 had expired. The board acknowledged that these resales may have been technical violations of Section 5 because of the early affiliate sales. Both individuals made written rescission offers at the original purchase price, none of which were accepted, and the company believes this reduces the risk of contingent liability and future enforcement or private claims.
Redox International Group filed an amendment to correct details about prior resales of restricted common stock by company affiliates. The original disclosure said 1,725,000 restricted shares were resold to eleven non-U.S. purchasers; the corrected figure is 1,325,000 shares sold to eight non-U.S. purchasers outside the United States.
Between August 6, 2024 and January 15, 2025, affiliates Dr. Han-Wen Ou and Mr. Hsun-Chih Lee resold these restricted shares in private transactions before the one-year distribution compliance period under Regulation S Rule 904 had expired. The board acknowledged that these resales may have been technical violations of Section 5 because of the early affiliate sales. Both individuals made written rescission offers at the original purchase price, none of which were accepted, and the company believes this reduces the risk of contingent liability and future enforcement or private claims.